On October 13, 2025 Artios Pharma Limited ("Artios"), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response ("DDR") in cancer, reported an upcoming oral presentation highlighting the company’s DNA polymerase Theta (Polθ) inhibitor, ART6043, at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2025, taking place between October 17-21, 2025, in Berlin, Germany (Press release, Artios Pharma, OCT 13, 2025, View Source [SID1234656576]). ART6043 is a potential first-in-class, selective DNA polymerase domain inhibitor being developed in combination with the PARP inhibitor, olaparib, in patients with cancers that harbor DDR defects.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will feature the first clinical results for ART6043 from the Phase 1/2a study (NCT05898399), including safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with advanced solid tumors. This will be the first time that clinical activity for a therapeutic candidate targeting Polθ in humans will be presented.
Details of the oral presentation:
Abstract Title: First data disclosure of the first-in-class DNA polymerase theta inhibitor, ART6043, as monotherapy and in combination with olaparib, in patients with molecularly-selected advanced solid tumors
Session Category and Title: Mini oral session: Developmental therapeutics
Date: Friday, October 17, 2025
Time: 4:30 – 4:35 PM CEST
Presenter: Dr. Timothy A. Yap, VP and Head of Clinical Development in the Therapeutics Discovery Division at The University of Texas MD Anderson Cancer Center
Location: Heidelberg Auditorium, Hall 6.2
The abstract is available on the ESMO (Free ESMO Whitepaper) Congress website.
Artios will issue a press release detailing the data presented at the conference following the oral presentation at ESMO (Free ESMO Whitepaper).
About ART6043
ART6043 is a potential first-in-class, selective, orally bioavailable, small‑molecule inhibitor of the polymerase domain of DNA polymerase Theta (Polθ), a DNA repair enzyme that is preferentially expressed in cancer cells but is virtually absent in most healthy tissues. By inhibiting Polθ, ART6043 targets microhomology mediated end joining (MMEJ) to exploit tumor dependence on error-prone DNA repair, with broad rationale for use as monotherapy and in combination with PARP inhibition and other DNA-damaging modalities. Artios’ differentiated approach is evaluating ART6043 with olaparib in molecularly defined solid tumors, including settings of BRCA variants and PARP inhibitor resistance, to enhance target engagement and anti-tumor activity while maintaining tolerability.